10 results about "HIV envelope protein" patented technology

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises:i. an amino acid sequence that binds to a V1 / V2 apex glycan epitope;ii. an amino acid sequence that binds to a V3-base glycan region epitope;iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope;iv. an amino acid sequence that binds to a gp120 / gp41 interface epitope; andv. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope.

The application discloses a kind of based on HIV envelope protein chimeric exosome and its preparation method and application, belong to biological medicine technical field.The application first constructs the cell line of stable expression HIV envelope protein Env, obtains engineered exosome from cell culture supernatant separation and purification;The exosome is used as immunogen combined with adjuvant immunization experimental animal, and high-efficiency induction specific humoral immune response;Again, obtain Env antigen specificity single B cell by flow cytometry sorting, obtain antibody variable region gene by single cell lysis, reverse transcription and nest PCR amplification, cloning to expression vector and expressing in mammalian cell, finally, HIV specific neutralizing antibody is screened by binding activity, affinity and neutralizing activity;The application is combined with single B cell antibody screening technology by embedding HIV Env antigen in the form of membrane combination in exosome surface, and realizes the synergistic optimization of antigen delivery and antibody screening process.

This disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof which have uses in vaccination methods or therapeutic strategies. In certain embodiments, this disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof, comprising an arginine (R) at position 166, glutamine (Q) at position 170, and an amino acid histidine (H) at position 173. In certain embodiments, this disclosure relates to nucleic acids and recombinant vectors encoding said proteins.

To provide a multispecific antigen-binding molecule targeting HIV and a method for its use. [Solution] A multispecific antigen-binding molecule is provided, comprising a bispecific antibody that binds to CD3 containing the HIV envelope protein gp120 and to the HIV antigen. Methods of using such an antigen-binding molecule to treat or prevent HIV infection are also provided. In some embodiments, the multispecific or bispecific molecule comprises a first antigen-binding domain targeting human CD3, which is a single-chain variable fragment (scFv) fused to Fc, while a second antigen-binding domain targeting the HIV antigen (e.g., gp120 or gp41) consists of a Fab antigen-binding fragment fused to Fc.

The invention discloses a preparation method of an HIV (Human Immunodeficiency Virus) envelope protein gp160. The preparation method comprises an effective interception and selection mode of amino acid sequences of envelope proteins gp160-I and gp160-II of HIV-I and HIV-II, an optimized nucleotide sequence, an expression plasmid construction method and a purification and preservation method. The gp160-I protein and the gp160-II protein are expressed through mammalian cells, the protein expression efficiency and the protein folding modification accuracy are greatly improved by adding the artificial signal peptide and the JSD promoter, and the gp160-I protein and the gp160-II protein have high biological activity and thermal stability and have the advantages that fermentation is easy to amplify, separation and purification are easy, and the coating use amount is low.

The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises: i. an amino acid sequence that binds to a V1 / V2 apex glycan epitope; ii. an amino acid sequence that binds to a V3-base glycan region epitope; iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope; iv. an amino acid sequence that binds to a gp120 / gp41 interface epitope; and v. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope.

Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.

The invention belongs to the technical field of biological medicines, and particularly relates to application of TNFR2 in preparation of a medicine for treating HIV infection. It is found for the first time that TNFR2 protein can inhibit infection of HIV pseudoviruses on CD4 cells by blocking combination of HIV envelope protein gp120 and CD4. Compared with the prior art, the invention has the following advantages: 1, experimental evidence is provided for the combination of TNFR2 and gp120 for the first time; 2, the binding site of the TNFR2 on the gp120 is close to that of the CD4, and the binding of the gp120 and the CD4 cell can be blocked; and 3, it is proved for the first time that the TNFR2 protein can inhibit infection of HIV pseudovirus on cells. The invention has important theoretical and practical meanings for researching the inhibition of the TNFR2 protein on HIV (Human Immunodeficiency Virus) infection.

Immunization strategies to naturally guide the maturation of antibodies against the human immunodeficiency virus (HIV) in HIV-infected subjects are described. The strategies include immunization utilizing an HIV envelope protein (Env) that binds germline (gl) B cells combined with taking HIV-infected subjects off of anti-viral medications, allowing natural virus to guide the maturation of gl B cells activated by the immunization. When B cells effectively mature against the HIV virus. HIV-infected subjects may remain off of anti-viral medications.